We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
CHEMM.CO

Price
686.50
Stock movement down
-14.50 (-2.07%)
Company name
ChemoMetec A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Devices
Market cap
11.95B
Ent value
11.76B
Price/Sales
57.42
Price/Book
17.74
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
181.76
Forward P/E
53.49
PEG
-
EPS growth
25.80%
1 year return
36.21%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-12-15

DIVIDENDS

CHEMM.CO does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E181.76
Price to OCF90.31
Price to FCF100.73
Price to EBITDA128.33
EV to EBITDA126.32

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales57.42
Price to Book17.74
EV to Sales56.52

FINANCIALS

Per share

Loading...
Per share data
Current share count17.40M
EPS (TTM)-
FCF per share (TTM)-

Income statement

Loading...
Income statement data
Revenue (TTM)-
Gross profit (TTM)-
Operating income (TTM)-
Net income (TTM)-
EPS (TTM)-
EPS (1y forward)12.83

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash341.85M
Net receivables79.62M
Total current assets543.16M
Goodwill7.35M
Intangible assets145.69M
Property, plant and equipment205.97M
Total assets828.05M
Accounts payable16.08M
Short/Current long term debt0.00
Total current liabilities146.99M
Total liabilities154.69M
Shareholder's equity673.36M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-
Capital expenditures (TTM)-
Free cash flow (TTM)-
Dividends paid (TTM)-

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open702.50
Daily high702.50
Daily low686.50
Daily Volume20K
All-time high1128.00
1y analyst estimate-
Beta1.59
EPS (TTM)-
Dividend per share0.00
Ex-div date15 Oct 2021
Next earnings date4 Feb 2026

Downside potential

Loading...
Downside potential data
CHEMM.COS&P500
Current price drop from All-time high-39.14%-1.22%
Highest price drop-68.33%-19.00%
Date of highest drop11 Oct 20248 Apr 2025
Avg drop from high-51.29%-2.64%
Avg time to new high-6 days
Max time to new high297 days89 days
COMPANY DETAILS
CHEMM.CO (ChemoMetec A/S) company logo
Marketcap
11.95B
Marketcap category
Large-cap
Description
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops XcytoMatic 30 cell counter and Xcyto 5, a versatile cell analyzer. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerod, Denmark.
Employees
170
Investor relations
-
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
ChemoMetec A/S recently reported first-quarter 2025 revenue exceeding forecasts alongside details of new product launches and a planned organizational restructuring. An important development is the co...
November 12, 2025
ChemoMetec (CPSE:CHEMM) has been on investors’ watchlists with a sharp upswing in its share price in the past 3 months. The stock is up over 50% during this period and has caught the attention of the ...
November 11, 2025
ANNOUNCEMENT NO. 298 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions r...
November 7, 2025
Trading statement for Q1 2025/26 (1 July - 30 September 2025) Growth in revenue and operating profit Revenue was up by 8% in Q1 2025/26 (11% at constant exchange rates) to DKK 124.6 million from DKK 1...
November 6, 2025
ANNOUNCEMENT NO. 295 28 October 2025 Upgrade of guidance ChemoMetec experiences an increased interest in its technology, not the least the XcytoMatic platform, and consequently expects a positive tren...
October 28, 2025
ANNOUNCEMENT NO. 294 9 October 2025 Procedure of the Annual General Meeting The Annual General Meeting of ChemoMetec A/S was held on 9 October 2025 at 5.30 p.m. at Nordsjællands KonferenceCenter. At t...
October 9, 2025
As the European markets navigate a complex landscape of interest rate policies and trade tensions, the pan-European STOXX Europe 600 Index has remained relatively stable, while major stock indexes in ...
October 2, 2025
ANNOUNCEMENT NO. 292 11 September 2025 Annual Report 2024/25 (1 July 2024 - 30 June 2025) Growing revenue and EBITDA ChemoMetec’s revenue grew by 22% to DKK 495.6 million in 2024/25, and operating pro...
September 11, 2025
ANNOUNCEMENT NO. 291 11 September 2025 Guidance for the 2025/26 financial year ChemoMetec today approved the annual report for 2024/25, including the guidance for 2025/26, which is considered inside i...
September 11, 2025
As European markets experience a lift, buoyed by hopes of lower U.S. borrowing costs and a surge in business activity, investors are turning their attention to small-cap stocks that might offer unique...
August 29, 2025
Next page